Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
22 juin 2022 09h31 HE
|
Intrommune Therapeutics
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Global Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight
20 juin 2022 12h00 HE
|
DelveInsight Business Research LLP
Las Vegas, USA, June 20, 2022 (GLOBE NEWSWIRE) -- Global Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight Food Allergy Pipeline constitutes 35+...
Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory
01 juin 2022 13h33 HE
|
Intrommune Therapeutics
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
Worldwide Allergy Immunotherapy Industry to 2028 - Increasing Approval of Allergy Immunotherapy by Regulatory Authorities are Driving Growth
28 avr. 2022 07h23 HE
|
Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapy Market, by Treatment Type, by Allergy Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity...
Outlook on the Meal Kit Delivery Services Global Market to 2030: Online Segment Accounted for the Largest Revenue Share of More Than 63.2% in 2021
21 avr. 2022 06h43 HE
|
Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Meal Kit Delivery Services Market Size, Share & Trends Analysis Report by Offering (Heat & Eat, Cook & Eat), by Service (Single,...
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
06 avr. 2022 08h30 HE
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
New Report Finds Major Gaps in Child Care Policies for Food Allergy Nationwide
25 févr. 2022 06h50 HE
|
Asthma and Allergy Foundation of America
Washington, D.C., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) and the Elijah-Alavi Foundation (EAF) released “Child Care Policies for Food Allergy:...
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
08 févr. 2022 08h30 HE
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing in Fully Enrolled Cohort 2 Intrommune Launches Series B Financing NEW YORK, Feb. 08, 2022 (GLOBE...
Allergy Immunoassay Market Brief: Sophistication in Testing is Leading to More Automated Effective Testing
25 janv. 2022 05h23 HE
|
Research and Markets
Dublin, Jan. 25, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunoassay Brief" report has been added to ResearchAndMarkets.com's offering. Allergies are a number of conditions that are caused by...
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
21 déc. 2021 09h39 HE
|
Intrommune Therapeutics
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...